Attaya Suvannasankha

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 14

Top Topics

Acute Lymphoblastic Leukemia

Multiple Myeloma

Top Venues

Nature communications

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Research square

This page only lists publications with an associated author ORCID identifier.

Publications

Naresh Bumma, Joshua Richter, Sundar Jagannath, Hans C Lee, James E Hoffman, Attaya Suvannasankha, Jeffrey A Zonder, Mansi R Shah, Suzanne Lentzch, Rachid C Baz, Joseph J Maly, Swathi Namburi, Matthew J Pianko, Jing Christine Ye, Ka Lung Wu, Rebecca W Silbermann, Chang-Ki Min, Marie-Christiane Vekemans, Markus Munder, Ja Min Byun, Joaquin Martinez Lopez, Kaniel Cassady, Michelle DeVeaux, Dhruti Chokshi, Anita Boyapati, Anasuya Hazra, George D Yancopoulos, L Andres Sirulnik, Karen Rodriguez Lorenc, Glenn S Kroog, Yariv Houvras, Madhav V Dhodapkar
Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Naresh Bumma, Joshua Richter, Sundar Jagannath, Hans C Lee, James E Hoffman, Attaya Suvannasankha, Jeffrey A Zonder, Mansi R Shah, Suzanne Lentzch, Rachid C Baz, Joseph J Maly, Swathi Namburi, Matthew J Pianko, Jing Christine Ye, Ka Lung Wu, Rebecca W Silbermann, Chang-Ki Min, Marie-Christiane Vekemans, Markus Munder, Ja Min Byun, Joaquin Martinez Lopez, Kaniel Cassady, Michelle DeVeaux, Dhruti Chokshi, Anita Boyapati, Anasuya Hazra, George D Yancopoulos, L Andres Sirulnik, Karen Rodriguez Lorenc, Glenn S Kroog, Yariv Houvras, Madhav V Dhodapkar
Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Travis S Johnson, Parvathi Sudha, Enze Liu, Nathan Becker, Sylvia Robertson, Patrick Blaney, Gareth J Morgan, Vivek S Chopra, Cedric Dos Santos, Michael Nixon, Kun Huang, Attaya Suvannasankha, Mohammad Abu Zaid, Rafat Abonour, Brian A Walker
1q amplification and PHF19 expressing high-risk cells are associated with relapsed/refractory multiple myeloma. Nature communications 15 (1) (2024)
Travis S Johnson, Parvathi Sudha, Enze Liu, Nathan Becker, Sylvia Robertson, Patrick Blaney, Gareth J Morgan, Vivek S Chopra, Cedric Dos Santos, Michael Nixon, Kun Huang, Attaya Suvannasankha, Mohammad Abu Zaid, Rafat Abonour, Brian A Walker
1q amplification and PHF19 expressing high-risk cells are associated with relapsed/refractory multiple myeloma. Nature communications 15 (1) (2024)
Travis S Johnson, Parvathi Sudha, Enze Liu, Nathan Becker, Sylvia Robertson, Patrick Blaney, Gareth J Morgan, Vivek S Chopra, Cedric Dos Santos, Michael Nixon, Kun Huang, Attaya Suvannasankha, Mohammad Abu Zaid, Rafat Abonour, Brian A Walker
1q amplification and PHF19 expressing high-risk cells are associated with relapsed/refractory multiple myeloma. Nature communications 15 (1) (2024)
Attaya Suvannasankha, Nizar Bahlis, Suzanne Trudel, Katja Weisel, Christian Koenecke, Albert Oriol, Peter M Voorhees, Aranzazu A Alonso, Natalie S Callander, María-Victoria Mateos, Nishitha Reddy, Shawn Hakim, John LaMacchia, Nashita Patel, Danaé Williams, Roxanne C Jewell, Xiangdong Zhou, Ira Gupta, Joanna Opalinska, Ajay K Nooka
Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma. Cancer (2024)
Travis S Johnson, Parvathi Sudha, Enze Liu, Nathan Becker, Sylvia Robertson, Patrick Blaney, Gareth J Morgan, Vivek S Chopra, Cedric Dos Santos, Michael Nixon, Kun Huang, Attaya Suvannasankha, Mohammad Abu Zaid, Rafat Abonour, Brian A Walker
1q amplification and PHF19 expressing high-risk cells are associated with relapsed/refractory multiple myeloma. Nature communications 15 (1) (2024)
Naresh Bumma, Joshua Richter, Sundar Jagannath, Hans C Lee, James E Hoffman, Attaya Suvannasankha, Jeffrey A Zonder, Mansi R Shah, Suzanne Lentzch, Rachid C Baz, Joseph J Maly, Swathi Namburi, Matthew J Pianko, Jing Christine Ye, Ka Lung Wu, Rebecca W Silbermann, Chang-Ki Min, Marie-Christiane Vekemans, Markus Munder, Ja Min Byun, Joaquin Martinez Lopez, Kaniel Cassady, Michelle DeVeaux, Dhruti Chokshi, Anita Boyapati, Anasuya Hazra, George D Yancopoulos, L Andres Sirulnik, Karen Rodriguez Lorenc, Glenn S Kroog, Yariv Houvras, Madhav V Dhodapkar
Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Attaya Suvannasankha, Nizar Bahlis, Suzanne Trudel, Katja Weisel, Christian Koenecke, Albert Oriol, Peter M Voorhees, Aranzazu A Alonso, Natalie S Callander, María-Victoria Mateos, Nishitha Reddy, Shawn Hakim, John LaMacchia, Nashita Patel, Danaé Williams, Roxanne C Jewell, Xiangdong Zhou, Ira Gupta, Joanna Opalinska, Ajay K Nooka
Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma. Cancer 130 (15) (2024)
Naresh Bumma, Joshua Richter, Sundar Jagannath, Hans C Lee, James E Hoffman, Attaya Suvannasankha, Jeffrey A Zonder, Mansi R Shah, Suzanne Lentzch, Rachid C Baz, Joseph J Maly, Swathi Namburi, Matthew J Pianko, Jing Christine Ye, Ka Lung Wu, Rebecca W Silbermann, Chang-Ki Min, Marie-Christiane Vekemans, Markus Munder, Ja Min Byun, Joaquin Martinez Lopez, Kaniel Cassady, Michelle DeVeaux, Dhruti Chokshi, Anita Boyapati, Anasuya Hazra, George D Yancopoulos, L Andres Sirulnik, Karen Rodriguez Lorenc, Glenn S Kroog, Yariv Houvras, Madhav V Dhodapkar
Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (22) (2024)
Travis S Johnson, Parvathi Sudha, Enze Liu, Nathan Becker, Sylvia Robertson, Patrick Blaney, Gareth J Morgan, Vivek S Chopra, Cedric Dos Santos, Michael Nixon, Kun Huang, Attaya Suvannasankha, Mohammad Abu Zaid, Rafat Abonour, Brian A Walker
1q amplification and PHF19 expressing high-risk cells are associated with relapsed/refractory multiple myeloma. Nature communications 15 (1) (2024)
Brian A Walker, Travis S Johnson, Parvathi Sudha, Enze Liu, Patrick Blaney, Gareth J Morgan, Vivek Chopra, Cedric Dos Santos, Michael Nixon, Kun Huang, Attaya Suvannasankha, Mohammad Abu Zaid, Rafat Abonour
Identifying 1q amplification and PHF19 expressing high-risk cells associated with relapsed/refractory multiple myeloma. Research square (2023)
Ajay K Nooka, Adam D Cohen, Hans C Lee, Ashraf Z Badros, Attaya Suvannasankha, Natalie Callander, Al-Ola Abdallah, Suzanne Trudel, Ajai Chari, Edward N Libby, Maria Chaudhry, Malin Hultcrantz, K Martin Kortüm, Rakesh Popat, Douglas Sborov, Shawn Hakim, Eric Lewis, Boris Gorsh, Bharat Bhushan, Astrid McKeown, Ira Gupta, Joanna Opalinska, Paul G Richardson, Sagar Lonial
Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial. Cancer (2023)
Adam David Cohen, Maria-Victoria Mateos-Manteca, Yael C Cohen, Paula Rodriguez Otero, Juan José Lahuerta, Niels W C J van de Donk, Thomas G Martin, Attaya Suvannasankha, Kevin C De Braganca, Christina Corsale, Jordan M Schecter, Helen Varsos, William Deraedt, Liwei Wang, Martin Vogel, Tito Roccia, Xiaoying Xu, Pankaj Mistry, Enrique Zudaire, Muhammad Akram, Tonia Nesheiwat, Lida Pacaud, Irit Avivi, Jesús San F Miguel
Efficacy and safety of cilta-cel in patients with progressive MM after exposure to other BCMA-targeting agents. Blood (2022)